AMIX (Autonomix Medical) Other Long-Term Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $5.77
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical Other Long-Term Liabilities?

Autonomix Medical AMIX -12.48% 15 Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Autonomix Medical's other long-term liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Autonomix Medical's annual other long-term liabilities increased from Mar. 2024 ($-0.00 Mil) to Mar. 2025 ($0.00 Mil) but then stayed the same from Mar. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Autonomix Medical Other Long-Term Liabilities Related Terms

Autonomix Medical Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical Other Long-Term Liabilities Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
0.00 -0.00 0.00 0.00

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AMIX
15GF Score
Autonomix Medical Inc AMIX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
Autonomix Medical (AMIX) has a Other Long-Term Liabilities of $0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Autonomix Medical and its competitors.
Is Autonomix Medical's Other Long-Term Liabilities too high?
Autonomix Medical's current Other Long-Term Liabilities is $0.00 Mil. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Other Long-Term Liabilities compare to BJDX and LUDG?
Autonomix Medical's Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Autonomix Medical and its competitors. Autonomix Medical's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Other Long-Term Liabilities of $0.00 Mil. The current Other Long-Term Liabilities is $0.00 Mil. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.77
Price